尼日利亚HIV感染者中的低水平病毒血症:一项回顾性纵向队列研究
首次病毒载量检测中,低水平病毒血症占16.0%(64480/402668),病毒学非抑制占11.4%(46051/402668);低水平病毒血症患者病毒学失败风险升高(校正相对风险2.20,95%CI 1.98-2.43;p<0.0001)。作者建议将监测基准和目标从低于1000拷贝/mL修订为低于50拷贝/mL。
要点
- 首次病毒载量中低水平病毒血症占16.0%,病毒学非抑制占11.4%。
- 低水平病毒血症患者病毒学失败风险升高(校正相对风险2.20,95%CI 1.98-2.43)。
- 作者建议将监测目标从低于1000拷贝/mL修订为低于50拷贝/mL。
核心结论
- 低水平病毒血症患者病毒学非抑制和失败风险升高。
- 项目应将监测基准和目标从低于1000拷贝/mL修订为低于50拷贝/mL,以加强临床结局并追踪疫情控制进展。
研究设计与样本
- 回顾性纵向队列研究,使用既往收集的纵向患者数据。
- 纳入尼日利亚18个州1005家机构中≥18岁、已启动并接受至少24周ART的HIV感染者。
- 估算病毒学抑制(≤50拷贝/mL)、低水平病毒血症(51-999拷贝/mL)、病毒学非抑制(≥1000拷贝/mL)和病毒学失败(≥2次连续病毒学非抑制结果)的发生率。
- 采用对数二项回归和混合效应 logistic 回归分析低水平病毒血症、病毒学非抑制和病毒学失败的风险。
主要发现
- 低水平病毒血症患者病毒学失败风险升高(校正相对风险2.20,95%CI 1.98-2.43;p<0.0001)。
- 与病毒学抑制患者相比,低水平病毒血症患者(即使51-199拷贝/mL)下次病毒载量检测时低水平病毒血症和病毒学非抑制的比值比升高。
- 在相同低水平病毒血症范围内,使用优化ART(即整合酶链转移抑制剂)的患者比值比低于使用非整合酶链转移抑制剂的患者(例如病毒载量400-999拷贝/mL后病毒载量≥1000拷贝/mL:整合酶链转移抑制剂比值比1.96,95%CI 1.79-2.13;p<0.0001;非整合酶链转移抑制剂比值比3.21,95%CI 2.90-3.55;p<0.0001)。
临床怎么用
- 作者建议项目将监测基准和目标从低于1000拷贝/mL修订为低于50拷贝/mL,以加强临床结局并追踪疫情控制进展。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV transmission can occur with a viral load of at least 200 copies per mL of blood and low-level viraemia can lead to virological failure; the threshold level at which risk for virological failure is conferred is uncertain. To better understand low-level viraemia prevalence and outcomes, we analysed retrospective longitudinal data from a large cohort of people living with HIV on antiretroviral therapy (ART) in Nigeria. METHODS: In this retrospective cohort study using previously collected longitudinal patient data, we estimated rates of virological suppression (≤50 copies per mL), low-level viraemia (51-999 copies per mL), virological non-suppression (≥1000 copies per mL), and virological failure (≥2 consecutive virological non-suppression results) among people living with HIV aged 18 years and older who initiated and received at least 24 weeks of ART at 1005 facilities in 18 Nigerian states. We analysed risk for low-level viraemia, virological non-suppression, and virological failure using log-binomial regression and mixed-effects logistic regression. FINDINGS: At first viral load for 402 668 patients during 2016-21, low-level viraemia was present in 64 480 (16·0%) individuals and virological non-suppression occurred in 46 051 (11·4%) individuals. Patients with low-level viraemia had increased risk of virological failure (adjusted relative risk 2·20, 95% CI 1·98-2·43; p<0·0001). Compared with patients with virological suppression, patients with low-level viraemia, even at 51-199 copies per mL, had increased odds of low-level viraemia and virological non-suppression at next viral load; patients on optimised ART (ie, integrase strand transfer inhibitors) had lower odds than those on non-integrase strand transfer inhibitors for the same low-level viraemia range (eg, viral load ≥1000 copies per mL following viral load 400-999 copies per mL, integrase strand transfer inhibitor: odds ratio 1·96, 95% CI 1·79-2·13; p<0·0001; non-integrase strand transfer inhibitor: 3·21, 2·90-3·55; p<0·0001). INTERPRETATION: Patients with low-level viraemia had increased risk of virological non-suppression and failure. Programmes should revise monitoring benchmarks and targets from less than 1000 copies per mL to less than 50 copies per mL to strengthen clinical outcomes and track progress to epidemic control. FUNDING: None.
引用
- Chun HM, Abutu A, Milligan K, et al. Low-level viraemia among people living with HIV in Nigeria: a retrospective longitudinal cohort study. Lancet Glob Health. 2022. PMID: 36400087. doi:10.1016/S2214-109X(22)00413-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。